GIMAP7 as a Potential Predictive Marker for Pan-Cancer Prognosis and Immunotherapy Efficacy

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Zhang W, Xu S, Wu G, Liu Y, Wang Q, Man C. Exploring the expression and preliminary function of chicken Gimap5 gene. PeerJ. 2019;7:e7618. doi:10.7717/peerj.7618
   PubMed Web of Science ®Google Scholar
• Krucken J, Schroetel RM, Muller IU, et al. Comparative analysis of the human gimap gene cluster encoding a novel GTPase family. Gene. 2004;341:291–304. doi:10.1016/j.gene.2004.07.005
   PubMed Web of Science ®Google Scholar
• Limoges MA, Cloutier M, Nandi M, Ilangumaran S, Ramanathan S. The GIMAP family proteins: an incomplete puzzle. Front Immunol. 2021;12:679739. doi:10.3389/fimmu.2021.679739
   PubMed Web of Science ®Google Scholar
• Deng S, Zhang Z, Lu X, Zhou Q, Xia S, Li M. Systemic analyses of expression patterns and clinical features for GIMAPs family members in lung adenocarcinoma. Aging. 2020;12(20):20413–20431. doi:10.18632/aging.103836
   PubMedGoogle Scholar
• Webb LM, Datta P, Bell SE, Kitamura D, Turner M, Butcher GW. GIMAP1 is essential for the survival of naive and activated B cells in vivo. J Immunol. 2016;196(1):207–216. doi:10.4049/jimmunol.1501582
   PubMed Web of Science ®Google Scholar
• Schnell S, Démollière C, van den Berk P, Jacobs H. Gimap4 accelerates T-cell death. Blood. 2006;108(2):591–599. doi:10.1182/blood-2005-11-4616
   PubMed Web of Science ®Google Scholar
• Schwefel D, Arasu BS, Marino SF, et al. Structural insights into the mechanism of GTPase activation in the GIMAP family. Structure. 2013;21(4):550–559. doi:10.1016/j.str.2013.01.014
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Hoadley KA, Yau C, Hinoue T, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291–304.e296. doi:10.1016/j.cell.2018.03.022
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi:10.1038/nature25501
   PubMed Web of Science ®Google Scholar
• Lan H, Yuan J, Chen X, et al. Multiomics profiling of the expression and prognosis of MCMs in endometrial carcinoma. Biosci Rep. 2021. doi:10.1042/BSR20211719
   Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Tooyserkani R, Rasaee MJ, Bandehpour M, WPM Löwik D. Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity. J Drug Target. 2021;29(7):771–782. doi:10.1080/1061186X.2021.1879087
   PubMed Web of Science ®Google Scholar
• Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res. 2019;7(10):1570–1573. doi:10.1158/2326-6066.CIR-19-0149
   PubMed Web of Science ®Google Scholar
• Wang S, He Z, Wang X, Li H, Liu XS. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. eLife. 2019;8:e49020
   PubMed Web of Science ®Google Scholar
• Kaderbhaï C, Tharin Z, Ghiringhelli F. The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer. Cancers. 2019;11(2). doi:10.3390/cancers11020201
   PubMed Web of Science ®Google Scholar
• Song Y, Pan Y, Liu J. The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma. Cancer Manag Res. 2019;11:7455–7472. doi:10.2147/CMAR.S201177
   PubMed Web of Science ®Google Scholar
• Mo X, Huang X, Feng Y, et al. Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients. Oncoimmunology. 2020;9(1):1832347. doi:10.1080/2162402X.2020.1832347
   PubMed Web of Science ®Google Scholar
• Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater. 2021;6(7):1973–1987. doi:10.1016/j.bioactmat.2020.12.010
   PubMed Web of Science ®Google Scholar
• Wu G, Liu J, Liu H, et al. An applicable inflammation-joined and nutrition-related prognostic indicator in patients with colorectal cancer. Front Oncol. 2021;11(2332):644670.
   PubMed Web of Science ®Google Scholar
• Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204–7218. doi:10.18632/oncotarget.23208
   PubMedGoogle Scholar
• Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285(16):2944–2971. doi:10.1111/febs.14466
   PubMed Web of Science ®Google Scholar
• Yue Y, Lian J, Wang T, et al. Interleukin-33-nuclear factor-κB-CCL2 signaling pathway promotes progression of esophageal squamous cell carcinoma by directing regulatory T cells. Cancer Sci. 2020;111(3):795–806. doi:10.1111/cas.14293
   PubMed Web of Science ®Google Scholar
• Liu J, Huang X, Liu H, et al. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients. J Transl Med. 2021;19(1):27. doi:10.1186/s12967-020-02638-9
   PubMed Web of Science ®Google Scholar
• Ciucci T, Bosselut R. Gimap and T cells: a matter of life or death. Eur J Immunol. 2014;44(2):348–351. doi:10.1002/eji.201344375
   PubMed Web of Science ®Google Scholar
• Nitta T, Nasreen M, Seike T, et al. IAN family critically regulates survival and development of T lymphocytes. PLoS Biol. 2006;4(4):e103. doi:10.1371/journal.pbio.0040103
   PubMed Web of Science ®Google Scholar
• Nitta T, Takahama Y. The lymphocyte guard-IANs: regulation of lymphocyte survival by IAN/GIMAP family proteins. Trends Immunol. 2007;28(2):58–65. doi:10.1016/j.it.2006.12.002
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang L, Xu X, et al. Transcriptome-based network analysis unveils eight immune-related genes as molecular signatures in the immunomodulatory subtype of triple-negative breast cancer. Front Oncol. 2020;10:1787. doi:10.3389/fonc.2020.01787
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. doi:10.1056/NEJMc1713444
   PubMed Web of Science ®Google Scholar
• Huang J, Liu H, Zhao Y, et al. MicroRNAs expression patterns predict tumor mutational burden in colorectal cancer. Front Oncol. 2020;10:550986. doi:10.3389/fonc.2020.550986
   PubMed Web of Science ®Google Scholar
• Huang X, Liu J, Liu H, et al. A combined epithelial mesenchymal transformation and DNA repair gene panel in colorectal cancer with prognostic and therapeutic implication. Front Oncol. 2020;10:595182. doi:10.3389/fonc.2020.595182
   PubMed Web of Science ®Google Scholar
• Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409–1412. doi:10.1056/NEJMp1709968
   PubMed Web of Science ®Google Scholar